Ixaka Reports Positive Interim Data from Phase 3 Trial of REX-001 in Patients with Chronic Limb-Threatening Ischemia and Diabetes

Ixaka Reports Positive Interim Data from Phase 3 Trial of REX-001 in Patients with Chronic Limb-Threatening Ischemia and Diabetes

Ixaka (formerly Rexgenero) reported positive interim results from a phase 3 trial of its lead drug candidate, REX-001, evaluating REX-001 versus placebo in patients diagnosed with chronic limb-threatening ischemia (CLTI) and diabetes. Following unblinded prespecified statistical analysis of safety and efficacy results from the first 30% of enrolled patients evaluated 12 months after treatment, the data monitoring committee (DMC) recommended continuation of the study as planned. There were no significant safety concerns. Ixaka remains blinded to the data until the completion of the trial.

The SALAMANDER trial is a randomized double-blind placebo-controlled adaptive trial including diabetic patients with Rutherford category 5 CLTI and with complete ulcer healing as the primary endpoint. The trial is actively recruiting in multiple sites in Europe, including sites in the UK, Spain, Austria, Portugal, Poland, Hungary, the Netherlands, the Czech Republic, Latvia, Lithuania and Georgia.

In previous clinical trials, including a Phase 2 randomized controlled trial, complete ulcer healing occurred in 75% of treated patients (compared to 14% healing in the control group).

About REX...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee